Akzo Nobel Pharma: unites the activities of four business units:

Organon (focus on gynecology, psychiatry, cardiovascular diseases, immunology, and analgesia),
Intervet (veterinary vaccines and diagnostics);
Diosynth (large scale fermentation and cell culture) and
Nobilon (human influenza vaccines).

Visit the company website www.akzonobel.com for full information.

The Company
Akzo Nobel, based in The Netherlands, serves customers throughout the world with healthcare products, paints, coatings and chemicals. Consolidated sales for 2003 totalled EUR 13 billion.
Akzo Nobelís activities are conducted by business units, which report directly to the Board of Management. The Company currently employs approximately 64.500 people in more than 80 countries.

Akzo Nobel Pharma
The Pharma Group of Akzo Nobel unites the activities of four business units, is active in widely diverse areas of human and animal health care and recognized through the world as a leading contributor to the advancement of medicinal and veterinary science.

Organon
Organon has redesigned the R&D process and organization by concentrating on (preclinical) pharmacological validation within newly formed academic networks. Additionally, the scope of the first phases of drug discovery has been broadened to show proof-of-concept of novel therapeutic approaches in the clinical setting.
Organon focusses on gynecology, psychiatry, cardiovascular diseases, immunology, and analgesia.

Intervet
For many years R&D at Intervet has focused on a wide range of veterinary vaccines and pharmaceutical products for companion animals and livestock.
R&D efforts in 2003 resulted in key registrations in major countries for canine, equine, poultry, swine and fish vaccines. In addition, four diagnostic tests were licensed.

Diosynth
Following the acquisition of a biotechnology foothold in the United States (CBSI), Diosynth completed the integration of its R&D infrastructure. A large scale fermentation and cell culture facility has been constructed, which will be validated in 2004. In addition, a novel peptide synthesis process (DioRaSPP) has been taken into operation.

Nobilon
A business strategy has been formulated. During the starting phase focus will be on the development of human influenza vaccines.

www.akzonobel.com